December 21, 2015.
FDA News reports that Eli Lilly has put a premium price tag on its new lung cancer drug Portrazza: $8,000 per treatment cycle.
FDA approved the drug, which is indicated for patients with squamous non-small cell lung cancer, in late November.
Lilly spokeswoman Carla Cox said the average patient will require six courses of treatment, which at $8,000 for each cycle works out to $48,000. But, FDA News adds, "she stressed that very few patients would ever pay this price, due to insurance coverage, medical assistance programs and price negotiations between industry and insurers".
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.